Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders

doi:10.4291/wjgp.v6.i4.181

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7040)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

630

WORD

350

HTML

3300

Figures (1-1)

199

Sum=4479

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1024

Download

1537

Sum=2561

Nov 15, 2015 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pathophysiology

ISSN

2150-5330

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 181-192
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.181

Open in New Tab Full Size Figure Download Figure

Figure 1 Proposed algorithm for treatment management of inflammatory bowel disease patients who are either Epstein-Barr virus seropositive or negative. ¹EBV monospot or EBV IgM have not been shown to be helpful in in determining serostatus; ²EBV viral load should be done by polymerase chain reaction in whole blood in EDTA collection tube. EBV: Epstein-Barr virus; IBD: Inflammatory bowel disease; EBNA: Epstein-Barr virus-determined nuclear antigen; LPD: Lymphoproliferative disorders; VCA: Viral-capsid antigen; EDTA: Ethylenediaminetetraacetic acid.

Citation: Lam GY, Halloran BP, Peters AC, Fedorak RN. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol 2015; 6(4): 181-192
URL: https://www.wjgnet.com/2150-5330/full/v6/i4/181.htm
DOI: https://dx.doi.org/10.4291/wjgp.v6.i4.181